Lumos Diagnostics announcement overview

Lumos Diagnostics (ASX:LDX) has appointed Thermo Fisher Scientific's Fisher Healthcare as the distributor for FebriDx® in the United States. FebriDx® is a rapid point-of-care respiratory test that provides results in 10 minutes from a fingerstick blood sample. The US Food and Drug Administration cleared FebriDx® for marketing in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology, specifically for use in urgent care or emergency care settings.

Executive commentary on the partnership

We are very pleased to announce this partnership with Fisher Healthcare for FebriDx® distribution. We look forward to working together to accelerate the growth of FebriDx® via their network of customers across the US. - Doug Ward, CEO and Managing Director for Lumos Diagnostics

Summary of Lumos Diagnostics announcement

Lumos Diagnostics (ASX:LDX) has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to distribute FebriDx® in the United States. FebriDx® is a rapid point-of-care respiratory test that delivers results in 10 minutes from a fingerstick blood sample and has been cleared by the US Food and Drug Administration for use in urgent care or emergency care settings. The partnership aims to accelerate the growth of FebriDx® via Fisher Healthcare's network of customers across the US, further expanding the reach of Lumos Diagnostics' innovative diagnostic technologies.